NCT04368039 Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
| NCT ID | NCT04368039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nicholas Breitborde |
| Condition | Psychosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2019-12-04 |
| Primary Completion | 2026-12-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2019-12-04 with a primary completion date of 2026-12-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Eligibility Criteria
* Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5. * Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory . * No evidence of a pre-existing intellectual disability defined as a premorbid IQ \>70 as estimated using the Reading subtest of the Wide Range Achievement Test-4. * Ages 15-35 * Non-smoker for past six months * Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale * The American Association for Respiratory Care notes that "no absolute contraindications to oxygen therapy exist when indications \[for oxygen therapy\] are present."
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04368039 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 35 Years, studying Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04368039 currently recruiting?
Yes, NCT04368039 is actively recruiting participants. Contact the research team at nicholas.breitborde@osumc.edu for enrollment information.
Where is the NCT04368039 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT04368039 clinical trial?
NCT04368039 is sponsored by Nicholas Breitborde. The trial plans to enroll 20 participants.